GoodRx Holdings, Inc. (NASDAQ: GDRX), a leading healthcare platform, has successfully amended its credit agreement to extend the maturity date of its $100 million revolving credit facility. The amendment, effective as of February 20, 2024, pushes the maturity from October 11, 2024, to July 11, 2025.
The Fifth Amendment to the First Lien Credit Agreement involves GoodRx, as the borrower, alongside GoodRx Intermediate Holdings, LLC and other guarantors. Barclays (LON:BARC) Bank PLC served as the administrative agent for the deal, which included various lenders and parties.
The extension was secured without altering the other significant terms of the Credit Agreement, including the terms of the Loan Parties' obligations under the Credit Agreement's term loan facility.
For securing the extension, GoodRx paid an extension fee that amounted to 0.125% of the revolving commitments of each extending revolving lender. This strategic financial move provides GoodRx with continued flexibility in its capital structure.
The company's relationship with the lenders extends beyond this agreement, as the lenders and their affiliates have conducted, and may continue to conduct, various investment banking and commercial dealings with the Company and its related entities.
These transactions are part of the ordinary course of business and have involved, and may involve, the receipt of customary fees and commissions. The extension of the credit facility's maturity date provides an additional cushion for GoodRx to manage its finances amidst the dynamic healthcare market.
Investors and stakeholders can find the details of this financial maneuver in the company's recent SEC filing, which outlines the specifics of the Fifth Amendment and its implications for GoodRx's financial strategy. The information provided in this article is based on the press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.